Sample of public companies in psychedelics space
The psychedelics industry has witnessed the emergence of several public companies dedicated to advancing the research and development of psychedelic compounds. These companies are engaged in various aspects of the field, from drug discovery and clinical trials to the production and distribution of psychedelic-based therapies. Their presence in the stock market reflects the growing interest and investment in the therapeutic potential of psychedelics, signaling a potential shift in the way mental health disorders are treated in the future.
ATAI Life Sciences (NASDAQ: ATAI) Market Cap: $359.7 million
ATAI Life Sciences is actively developing a range of drug candidates derived from psychedelic substances, with a focus on compounds like ibogaine and ketamine. Their innovative approach aims to unlock new therapeutic potential in the psychedelic space.
Compass Pathways (NASDAQ: CMPS) Market Cap: $433.6 million
Compass Pathways is a key player in the field, specializing in the development of psilocybin-based therapy, notably COMP360. Their dedication to rigorously testing and advancing psilocybin's therapeutic applications marks them as leaders in the industry.
Cybin (NYSEMKT: CYBN) Market Cap: $79.6 million
Cybin is advancing CYB001, a clinical-stage psilocybin therapy, while actively exploring other promising psychedelic candidates in preclinical stages. Their commitment to research and development positions them for future breakthroughs.
Mind Medicine (NASDAQ: MNMD) Market Cap: $177.2 million
Mind Medicine is making significant strides in psychedelic research with three clinical-stage programs. Two of these programs focus on LSD, while the third incorporates the use of ibogaine. Their multidimensional approach demonstrates a commitment to addressing mental health challenges.
Numinus Wellness (OTC: NUMI.F) Market Cap: $62.6 million
Numinus Wellness is a holistic player in the industry, operating therapy centers while concurrently developing psychedelic drugs based on substances like MDMA and psilocybin. Their dual commitment to treatment and drug development sets them apart.
Seelos Therapeutics (NASDAQ: SEEL) Market Cap: $194.3 million
Seelos Therapeutics is actively pursuing four clinical-stage programs, one of which is an intranasal ketamine drug. Their diverse portfolio reflects their dedication to exploring various avenues within the psychedelics space.